Novartis

Novartis Commits $100M to Startup With Tech That Brings Peptides to Undruggable Targets

• Novartis’s alliance with Unnatural Products is pursuing next-generation peptide drugs for cardiovascular disease. • The startup already has drug R&D alliances with BridgeBio Phar

WHO renews commitment to a leprosy-free world, spotlighting partnership and progress ahead of World Leprosy Day

• WHO reaffirms leprosy elimination goal, highlighting partnership with Novartis. • 172,717 new cases reported worldwide in 2024, yet 55 regions zero cases. • Multidrug therapy (MD